David Blaine Ridley

David Blaine Ridley

Professor of the Practice of Economics

External Address: 
100 Fuqua Drive, Durham, NC 27708-0120
Internal Office Address: 
Duke Box 90120, 100 Fuqua Drive, Durham, NC 27708-0120
Phone: 
(919) 660-3784

David Ridley is the Dr. and Mrs. Frank A. Riddick Professor of the Practice of Business Administration. He is also the Faculty Director of Duke's Health Sector Management program. In his research, David examines innovation and pricing, especially in health care. He was the lead author of the paper proposing the priority review voucher program to encourage development of drugs for neglected diseases. The voucher program became law in the U.S. in 2007 and and created more than a billion dollars in value. David has published in economics journals (Journal of Public Economics), medical journals (Journal of the American Medical Association), and scientific journals (Nature Reviews Drug Discovery). David teaches in the daytime MBA and executive MBA programs. He received a PhD in economics from Duke University in 2001.

Education

  • Ph.D., Duke University 2001
  • M.A., Duke University 1995
  • B.A., University of Missouri at Columbia 1993

Ridley, D. B. “Herding versus Hotelling: Market entry with costly information.” Journal of Economics and Management Strategy 17, no. 3 (September 1, 2008): 607–31. https://doi.org/10.1111/j.1530-9134.2008.00188.x. Full Text

Ridley, David B. “International price comparisons for novel and follow-on drugs..” Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research 10, no. 6 (November 2007): 510–11. https://doi.org/10.1111/j.1524-4733.2007.00238.x. Full Text

Kyle, Margaret K., and David B. Ridley. “Would greater transparency and uniformity of health care prices benefit poor patients?.” Health Affairs (Project Hope) 26, no. 5 (September 2007): 1384–91. https://doi.org/10.1377/hlthaff.26.5.1384. Full Text

Grabowski, H. G., D. B. Ridley, and K. A. Schulman. “Entry and competition in generic biologics.” Managerial and Decision Economics 28, no. 4–5 (June 1, 2007): 439–51. https://doi.org/10.1002/mde.1352. Full Text Open Access Copy

Ridley, David B., Henry G. Grabowski, and Jeffrey L. Moe. “Developing drugs for developing countries..” Health Affairs (Project Hope) 25, no. 2 (March 2006): 313–24. https://doi.org/10.1377/hlthaff.25.2.313. Full Text Open Access Copy

Ridley, David B., Judith M. Kramer, Hugh H. Tilson, Henry G. Grabowski, and Kevin A. Schulman. “Spending on postapproval drug safety..” Health Aff (Millwood) 25, no. 2 (March 2006): 429–36. https://doi.org/10.1377/hlthaff.25.2.429. Full Text Open Access Copy

Ridley, D. B., and J. M. Kramer. “Postapproval drug safety: The authors respond [8].” Health Affairs 25, no. 4 (January 1, 2006): 1187–88. https://doi.org/10.1377/hlthaff.25.4.1184-a. Full Text

Ridley, David B., and Kirsten J. Axelsen. “Impact of Medicaid preferred drug lists on therapeutic adherence..” Pharmacoeconomics 24 Suppl 3 (January 2006): 65–78. https://doi.org/10.2165/00019053-200624003-00006. Full Text

Ridley, David B., and Judith M. Kramer. “Postapproval drug safety: The authors respond.” Health Affairs 25, no. 4 (2006): 1187–88. https://doi.org/10.1377/hlthaff.25.4.1187. Full Text

Pages